NCT06994299View on ClinicalTrials.gov

A Pilot Trial of Preoperative Irradiation With the STRIDE (Single Dose of Tremelimumab With Ongoing Durvalumab) Regimen (PRISM) for Resectable/Advanced Hepatocellular Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

July 1, 2027

Study Completion Date

July 1, 2028

Conditions
Hepatocellular Carcinoma (HCC)
Interventions
RADIATION

Radiation Therapy

Hypofractionated radiotherapy - 8Gy x3 fractions (week 0)

DRUG

Tremelimumab

Tremelimumab - single dose of 300 mg IV (week 0).

DRUG

Durvalumab

Durvalumab-500 mg IV every 4-weeks (weeks 0-3) prior to hepatic resection

PROCEDURE

Surgery

Hepatic resection

Trial Locations (1)

11355

New York-Presbyterian Weill Cornell Medical College, New York

All Listed Sponsors
lead

Weill Medical College of Cornell University

OTHER